Vascepa's Fast-Track Approval Path
Vascepa (icosapent ethyl) gained FDA approval for cardiovascular risk reduction in December 2020 via the 505(b)(2) pathway, building on its prior 2012 approval for triglyceride reduction. This allowed reliance on existing data for the expanded label, shortening development time compared to a full new drug application.[1]
Role of the REDUCE-IT Trial
The pivotal Phase 3 REDUCE-IT trial, completed in 2018, showed a 25% relative risk reduction in major cardiovascular events versus placebo in high-risk patients on statins. Its strong results—published in the New England Journal of Medicine—provided robust efficacy evidence, accelerating review after submission in 2019.[1][2]
FDA Priority Review Designation
Amarin requested and received priority review in March 2019, cutting the standard 10-month review to 6 months. This applies to drugs offering significant improvements in treating serious conditions, justified here by REDUCE-IT's cardiovascular outcomes data.[1][3]
Breakthrough Therapy Designation
Granted in 2017 based on interim REDUCE-IT data, this status offered FDA intensive guidance, rolling reviews, and senior involvement, expediting development and approval by years compared to standard timelines.[1][4]
Impact of Special Protocol Assessment
FDA's 2013 agreement on REDUCE-IT's design locked in the trial protocol early, minimizing delays from redesigns or disputes, a key efficiency booster.[1]
Comparison to Standard Timelines
Typical cardiovascular drugs take 10-12 years from Phase 3 start to approval; Vascepa's label expansion took under 3 years post-trial readout, driven by these mechanisms rather than fast-track (which was not used).[1][5] No major safety issues or advisory committee review further streamlined the process.
Sources
[1]: FDA Approval Letter for Vascepa (2020)
[2]: Bhatt et al., NEJM (2019) - REDUCE-IT Results
[3]: FDA Priority Review Explanation
[4]: FDA Breakthrough Therapy Details
[5]: DrugPatentWatch.com - Vascepa Timeline